The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis
The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
Kubra Bugdayli, MD, Ahmed Eldaboush, MD, Sanjana Aggarwal, MBBS, & Bonnie Bermas, MD |
Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by persistent fever at regular intervals, arthralgias or arthritis, rash, sore throat and neutrophilic leukocytosis.1,2 Significant elevation in ferritin levels is characteristic and tends to correlate with disease activity. Additional clinical features may include myalgias, lymphadenopathy, hepatosplenomegaly, serositis, myocarditis, abnormal liver function tests and development…
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
The FDA has approved the first interchangeable biosimilars for denosumab.
In a phase 3 trial, treatment with VX-548 led to statistically and clinically significant improvements in pain compared with placebo.
David Mecham, DO |
For the 2023 Image Competition, the ACR sought images representing a diverse range of patients with idiopathic inflammatory myopathies (IIMs) or IIM mimics. Pneumomediastinum & Ulcerative Cutaneous Dermatomyositis These images depict a 22-year-old woman with a recent diagnosis of anti-melanoma differentiation-associated gene 5 (MDA-5) antibody dermatomyositis who sought evaluation of worsening skin rashes and pleuritic…
Ryan Basen |
About 30 years ago, early in his career as a rheumatologist, Dirkjan van Schaardenburg, PhD, says patients with osteoarthritis experienced terrible problems with inflammation. The landscape has improved to the point that “people can live with it now,” he says. But they still need help. For example, osteoarthritis affects 7% of the global population, according…
Devyani Misra, MD, MS, & Jiha Lee, MD, MHS |
SAN DIEGO—Older adults with rheumatoid arthritis (RA) comprise two groups: those who have lived with diagnosed RA since an early age (young-onset RA) and those who have new-onset RA diagnosed at an older age (≥65 years), known as late-onset RA or, formerly, as elderly onset RA.1 Individuals with late-onset RA have more acute and systemic…